The effects of cognitive and behavioral therapies for anxiety disorders on depression: A meta-analysis. by Cuijpers, Pim et al.
VU Research Portal
The effects of cognitive and behavioral therapies for anxiety disorders on depression:
A meta-analysis.




DOI (link to publisher)
10.1017/S0033291716002348
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Cuijpers, P., Cristea, I. A., Weitz, E., Gentili, C., & Berking, M. (2016). The effects of cognitive and behavioral
therapies for anxiety disorders on depression: A meta-analysis. Psychological Medicine, 46, 3451-3462. [46].
https://doi.org/10.1017/S0033291716002348
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 26. May. 2021
The effects of cognitive and behavioural therapies
for anxiety disorders on depression: a meta-analysis
P. Cuijpers1,2*, I. A. Cristea3,4, E. Weitz1,2, C. Gentili4 and M. Berking5
1Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, The Netherlands
2EMGO Institute for Health and Care Research, Amsterdam, The Netherlands
3Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, Cluj-Napoca, Romania
4Department of General Psychology, University of Padova, Padova, Italy
5Department of Clinical Psychology and Psychotherapy, Friedrich-Alexander-University Erlangen-Nürnberg, Germany
Background. The effects of cognitive behavioural therapy of anxiety disorders on depression has been examined in pre-
vious meta-analyses, suggesting that these treatments have considerable effects on depression. In the current meta-ana-
lysis we examined whether the effects of treatments of anxiety disorders on depression differ across generalized anxiety
disorder (GAD), social anxiety disorder (SAD) and panic disorder (PD). We also compared the effects of these treatments
with the effects of cognitive and behavioural therapies of major depression (MDD).
Method. We searched PubMed, PsycINFO, EMBASE and the Cochrane database, and included 47 trials on anxiety
disorders and 34 trials on MDD.
Results. Baseline depression severity was somewhat lower in anxiety disorders than in MDD, but still mild to moderate
in most studies. Baseline severity differed across the three anxiety disorders. The effect sizes found for treatment of the
anxiety disorders ranged from g = 0.47 for PD, g = 0.68 for GAD and g = 0.69 for SAD. Differences between these effect
sizes and those found in the treatment of MDD (g = 0.81) were not significant in most analyses and we found few indica-
tions that the effects differed across anxiety disorders. We did find that within-group effect sizes resulted in significantly
(p < 0.001) larger effect sizes for depression (g = 1.50) than anxiety disorders (g = 0.73–0.91). Risk of bias was considerable
in the majority of studies.
Conclusions. Patients participating in trials of cognitive behavioural therapy for anxiety disorders have high levels of
depression. These treatments have considerable effects on depression, and these effects are comparable to those of treat-
ment of primary MDD.
Received 11 February 2016; Revised 16 July 2016; Accepted 26 July 2016; First published online 23 September 2016
Key words: Cognitive behavioural therapy, generalized anxiety disorder, major depression, panic disorder, social
anxiety disorder.
Introduction
Cognitive and behavioural therapies (CBT) have been
found to be effective in the treatment of anxiety disor-
ders, including social anxiety disorders (SAD;
Acarturk et al. 2009), generalized anxiety disorders
(GAD; Hunot et al. 2007; Cuijpers et al. 2014) and
panic disorder (PD; Sánchez-Meca et al. 2010).
Although some other types of treatment have been
developed for the treatment of anxiety disorders, like
psychodynamic (Milrod et al. 2007; Beutel et al. 2013)
and interpersonal psychotherapies (Cuijpers et al.
2016), cognitive and behavioural therapies have been
examined in dozens of randomized trials and have
consistently been shown to be effective in the treatment
of anxiety disorders with large effect sizes across disor-
ders. Treatment guidelines typically advise use of cog-
nitive and behavioural therapies as first-line treatments
of anxiety disorders (NICE, 2011).
The majority of patients suffering from an anxiety
disorder also suffer from depression, either as a co-
morbid depressive disorder or as subclinical depres-
sive symptoms (Goldberg et al. 2009). It is therefore
not surprising that in many randomized trials on cog-
nitive and behavioural therapies for anxiety disorders,
depression is included as one of the outcome mea-
sures. Although most trials use symptoms of anxiety
as the primary outcome measure, depression is typical-
ly used as one of the most important secondary out-
come measures.
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Meta-analyses of cognitive behavioural treatments of
anxiety disorders have examined the effects of these
treatments on depression. When these treatments
were compared with care-as-usual or waiting-list con-
trol groups, effect sizes typically found were between
d = 0.60 and 1.00 for GAD, SAD and PD (Mitte, 2005;
Hunot et al. 2007; Acarturk et al. 2009; Sánchez-Meca
et al. 2010; Cuijpers et al. 2014). These effect sizes cor-
respond well with effect sizes found for cognitive be-
havioural interventions aimed at depression (Cuijpers
et al. 2013; Ekers et al. 2014), suggesting that treatment
of anxiety disorders is also effective in reducing de-
pressive symptoms that are co-morbid with anxiety.
It should be noted that CBT for depression and the
anxiety disorders are not identical. Although both in-
clude techniques aimed at cognitive restructuring, be-
havioural activation, for example, has been found to
be effective in depression (Ekers et al. 2014), but is
not assumed to work in anxiety disorders. Exposure
has been developed for anxiety disorders, and relax-
ation works well in GAD, but less so in panic and de-
pression (Siev & Chambless, 2007).
What has not been examined so far, however, is
whether the effects of treatment of anxiety disorders
on depression differ for each of the specific anxiety dis-
orders. Previous meta-analyses suggest that the effects
of CBT of anxiety disorders result in comparable effect
sizes on depression, but this has not been tested. It has
also not been examined whether the effects of treat-
ment of anxiety disorders on depression differ signifi-
cantly from the effects of cognitive behavioural
treatment of depressive disorders. Previous meta-
analyses suggest that these effects are also comparable,
but again, this has not been tested.
Whether CBT for anxiety disorders also has an
effects on depression is important, because if these
effects are comparable across depression and anxiety
disorders, it would not be necessary to treat depression
separately from the anxiety disorder and clinicians can
assume that when an anxiety disorder is treated, de-
pression is also improved. It is also important because
it may simplify transdiagnostic treatments (Craske,
2012). From a theoretical point this is also an interest-
ing question, because if treating anxiety also affects de-
pression this could be seen as support for the notion
that both anxiety and depressive disorders should be
considered as variants of a broader category of neurot-
ic disorders (Goldberg et al. 2009).
We decided, therefore, to conduct a meta-analysis of
trials examining the effects of cognitive and behavioural
therapies for GAD, SAD and PD, in which we also
examined the effects of these treatments on depression.
We compared these outcomes with those of trials exam-
ining the effects of cognitive and behavioural therapies
for major depressive disorder (MDD) in adults.
Method
Identification and selection of studies
We searched four major bibliographical databases
(PubMed, PsycINFO, EMBASE and the Cochrane data-
base of randomized trials) by combining terms (both
MeSH terms and text words) indicative of SAD (such
as social phobia, social anxiety, public-speaking anx-
iety), GAD (such as worry and generalized anxiety),
and PD (such as panic, panic disorder), with filters
for randomized controlled trials. We also checked the
references of earlier meta-analyses of psychological
treatments for the included disorders. The deadline
for the searches was 14 August 2015.
For the identification of trials on CBT for depression,
we used an existing database of 1756 papers on the
psychological treatment of depression. This database
has been described in detail elsewhere (Cuijpers et al.
2008), and has been used in a series of earlier published
meta-analyses (www.evidencebasedpsychotherapies.
org). The database is continuously updated and was
developed through a comprehensive literature search
(from 1966 to January 2015) in which 17 061 abstracts
in PubMed (4007 abstracts), PsycINFO (3147),
EMBASE (5912) and the Cochrane Central Register
of Controlled Trials (3995) were examined. These
abstracts were identified by combining terms indica-
tive of psychological treatment and depression (both
MeSH terms and text words).
We included (a) randomized trials (b) in which a cog-
nitive or behavioural treatment (c) for adults (d) with
PD (with or without agoraphobia), generalized anxiety
disorder (GAD), social anxiety disorder (SAD), or
major depressive disorder (MDD) (e) was directly com-
pared to a control group (waiting list, care as usual,
placebo or other) and (f) in which the effects of the
treatment on depression [according to the Beck
Depression Inventory (BDI; Beck et al. 1961), the
BDI-II (Beck et al. 1996) or the Hamilton Rating Scale
for Depression (HAMD-17; Hamilton, 1960) was mea-
sured. Only studies in which subjects met diagnostic
criteria for the disorder according to a structured diag-
nostic interview (such as SCID, CIDI, or MINI) were
included. We focused only on depressive symptoms
as measured with BDI, the BDI-II and HAMD-17
because these are by far the most used outcome
instruments for depression in trials on anxiety disor-
ders, and because this focus allowed a direct compari-
son with studies on the treatment of depression, where
these instruments are also the most used outcome
measures.
Cognitive and behavioural therapies were defined as
therapies aimed at cognitive restructuring or at chan-
ging current anxiety behaviour. For depression we
included trials in which CBT (Cuijpers et al. 2013) or
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behavioural activation therapy (Ekers et al. 2014) was
examined. Studieson therapiesdeliveringonly (applied)
relaxation were excluded, as were studies on eye move-
ment desensitization and reprocessing, interpersonal
or psychodynamic therapies. Co-morbidmental or som-
atic disorders were not used as an exclusion criterion.
Studies on inpatients, adolescents and children (age
<18 years) were excluded. We also excluded mainten-
ance studies, aimed at people who had already recov-
ered or partly recovered after an earlier treatment. We
excluded these studies because their aim is different
from acute treatments and because including them
would lead to an increased level of clinical and probably
statisticalheterogeneity. Studies thatdidnot report suffi-
cient data to calculate standardized effect sizes were
excluded as well. Studies in English, German, and
Dutch were considered for inclusion.
Quality assessment and data extraction
We assessed the validity of included studies using four
criteria of the ‘Risk of bias’ assessment tool, developed
by the Cochrane Collaboration (Higgins et al. 2011).
This tool assesses possible sources of bias in randomized
trials, including the adequate generationof allocation se-
quence; the concealment of allocation to conditions; the
prevention of knowledge of the allocated intervention
(maskingofassessors); anddealingwith incompleteout-
come data (this was assessed as positive when
intention-to-treat analyses were conducted, meaning
that all randomized patients were included in the ana-
lyses). Assessment of the validity of the included studies
wasconductedby two independent researchers, anddis-
agreements were solved through discussion.
We also coded participant characteristics (disorder,
recruitment method, target group); characteristics of
the psychotherapies (treatment format, number of
sessions); and general characteristics of the studies
(country where the study was conducted, year of
publication).
Meta-analyses
For each comparison between a psychotherapy and a
control condition, the effect size indicating the differ-
ence between the two groups at post-test was calcu-
lated (Hedges’ g). Effect sizes were calculated by
subtracting (at post-test) the average score of the psy-
chotherapy group from the average score of the control
group, and dividing the result by the pooled standard
deviation. Because some studies had relatively small
sample sizes we corrected the effect size for small sam-
ple bias (Hedges & Olkin, 1985). If means and standard
deviations were not reported, we used the procedures
of the Comprehensive Meta-analysis software (version
3.3070; CMA) to calculate the effect size using
dichotomous outcomes; and if these were not available
either, we used other statistics (such a t value or p value)
to calculate the effect size.We also calculated (unstandar-
dized) mean differences that indicate the difference be-
tween treatment and control groups in terms of points
on the specific scale that was used (BDI, BDI-II,
HAMD-17). Furthermore, we calculated effect sizes indi-
cating the improvement from baseline to post-test for the
treatment groups in the studies. Because the values at
baseline and post-test are not independent of each other,
we assumed a conservative correlation between baseline
and post-test score of r = 0.70.
To calculate pooled mean effect sizes, we used the
Comprehensive Meta-Analysis computer program.
Because we expected considerable heterogeneity
among the studies, we employed a random-effects
pooling model in all analyses.
In order to assess baseline difference among patients
with GAD, SAD, PD and MDD, we pooled the mean
on BDI, BDI-II, HAMD-17 at baseline using the
means, standard deviations and number of the treat-
ment groups according to the procedures implemented
in CMA. Numbers needed to treat (NNT) were calcu-
lated using the formulae provided by Kraemer &
Kupfer (2006).
As a test of homogeneity of effect sizes, we calcu-
lated the I2 statistic, which is an indicator of heterogen-
eity in percentages. A value of 0% indicates no
observed heterogeneity, and larger values indicate in-
creasing heterogeneity, with 25% as low, 50% as mod-
erate, and 75% as high heterogeneity (Higgins et al.
2003). We calculated 95% confidence intervals around
I2 (Ioannidis et al. 2007), using the non-central
χ²-based approach within the heterogi module for
Stata (Orsini et al. 2006).
We conducted subgroup analyses according to the
mixed-effects model, in which studies within sub-
groups are pooled with the random-effects model,
while tests for significant differences between sub-
groups are conducted with the fixed-effects model.
For continuous variables, we used meta-regression
analyses to test whether there was a significant rela-
tionship between the continuous variable and effect
size, as indicated by a Z value and an associated
p value. Multivariate meta-regression analyses, with
the effect size as the dependent variable, were con-
ducted in CMA.
We tested for publication bias by inspecting the fun-
nel plot on primary outcome measures and by Duval &
Tweedie’s trim-and-fill procedure (Duval & Tweedie,
2000), which yields an estimate of the effect size after
publication bias has been taken into account (as imple-
mented in CMA). We also conducted Egger’s test of
the intercept to quantify the bias captured by the fun-
nel plot and test whether it was significant.
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Results
Selection and inclusion of studies
After examining a total of 27 429 abstracts (18 392 after
removal of duplicates), we retrieved 2928 full-text
papers for further consideration. We excluded 2747
of the retrieved papers. The PRISMA flowchart de-
scribing the inclusion process, including the reasons
for exclusion, is presented in Fig. 1. A total of 47 stud-
ies met inclusion criteria for this meta-analysis, 16
studies on GAD, 18 studies on PD, and 13 on SAD.
Apart from the studies on anxiety disorders, we
included 34 studies on MDD that used the BDI,
BDI-II and/or HAMD-17. Selected characteristics of
the included studies (81 in total) are reported in
Supplementary Appendix A and references are given
in Supplementary Appendix B.
Characteristics of included studies
The 81 studies included a total of 110 comparisons be-
tween a treatment and a control group (21 comparisons
for GAD, 19 for SAD, 28 for panic, and 42 for MDD)
and included a total of 5486 patients (3187 in the
CBT groups and 2299 in the control groups).
Sixty-three studies were aimed at adults in general,
seven were aimed at older adults and 11 at other
more specific target groups. Twenty-three studies
recruited patients exclusively from clinical popula-
tions, 46 recruited (also) from the community, and 12
used other recruitment methods.
In the 110 CBT conditions, the treatment was deliv-
ered in individual format in 60 studies, in group format
in 29 studies, in guided self-help format in 19 studies
and five studies used a mixed format. The number of
treatment sessions ranged from 3 to 26. In 55 studies
Fig. 1. PRISMA flowchart for the inclusion of studies. (Adapted from Moher et al. 2009.)
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a waiting-list control group was used, five used a pill
placebo control group, 16 had a care-as-usual control
group, and five another control condition. Forty-one
studies were conducted in North America, 29 in
Europe, and 11 in other countries.
Quality assessment
The quality of the studies varied. Thirty-two studies
reported an adequate sequence generation, while the
other 49 did not. Twenty-nine of the 81 studies
reported allocation to conditions by an independent
(third) party. Seventy-seven studies reported blinding
of outcome assessors or used only self-report outcomes
and 58 studies conducted intention-to-treat analyses.
Twenty-five studies met all four quality criteria, 34
met two or three criteria, and the remaining 22 studies
met one or none of the criteria.
Baseline differences among patients in treatment on
GAD, SAD and PD
We first examined whether the baseline scores on BDI,
BDI-II and HAMD-17 differed among patients with
GAD, SAD, and PD. The pooled means are reported
in Table 1. The difference between the three disorders
was significant for the HAMD-17, indicating that base-
line severity was lowest for SAD. There was also a
trend (p < 0.1) towards significance for the BDI suggest-
ing that baseline depression was lower in SAD.
However, the number of studies was very small in
some subgroups for BDI-II and HAMD-17. Scores be-
tween 10 and 18 on BDI indicate mild to moderate
(Beck et al. 1988), so on average patients with all
three anxiety disorders fell into this category.
When we included the studies on MDD in these sub-
group analyses, we found that all baseline severity scores
were higher in studies in depression than in the anxiety
disorders, and that was true for BDI, BDI-II and
HAMD-17.
Heterogeneity was very high in most analyses with
larger samples of studies, as is typically the case
when pooling absolute numbers (Higgins & Green,
2011, sections 9.4.4. and 9.4.8). However, because of
these significant baseline differences we decided to
add baseline scores in the multivariate analyses exam-
ining whether the effect sizes of the therapies differed
across disorders (see below).
Differential outcomes on depression of trials across
GAD, SAD and PD
We tested whether the effects of therapies on depres-
sion differed across the three anxiety disorders
(Table 2). A forest plot of the effects of the therapies
is given in Fig. 2. When we pooled all three depression
Table 1. Pooled mean baseline scores on the BDI, BDI-II and HAMD-17 in patients participating in cognitive and behavioural therapies for
GAD, SAD, PD and MDDa
Ncmp Mean 95% CI I




GAD 16 16.77 15.14–18.40 69 43–80 0.01 0.06
SAD 11 13.82 11.95–15.69 70 34–82
PD 26 16.00 14.71–17.28 73 58–81
MDD 22 23.68 17.03–30.32 100 –
BDI-IId
GAD 5 19.79 15.92–23.66 89 76–94 <0.001 0.18
SAD 4 15.88 11.71–20.05 79 11–90
PD
MDD 12 27.86 25.50–30.21 85 75–90
HAMD-17
GAD 5 14.42 11.29–17.56 85 60–92 <0.001 <0.001
SAD 4 8.18 7.23–9.14 30 0–76
PD 4 11.73 8.95–14.51 68 0–87
MDD 20 19.74 17.84–21.65 97 96–97
BDI, Beck Depression Inventory; HAMD-17, Hamilton Depression Rating Scale; GAD, Generalized anxiety disorder; SAD,
social anxiety disorder; PD, panic disorder; MDD, major depressive disorder; CI, Confidence interval; Ncmp, number of
comparisons; NNT, number needed to treat.
a According to the random-effects model.
b The p values in this column indicate whether the difference between the different disorders is significant: MDD included.
c The p values in this column indicate whether the difference between the different disorders is significant: MDD excluded.
d None of the studies on panic disorder used the BDI-II as outcome measure.
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outcome measures, we found no significant difference
across the three disorders (p = 0.35). This was also true
when we limited the analyses to studies with a low risk
of bias, although the number of studies was small.
When we looked at the three depression instruments
separately, we also found no significant differences
across the anxiety disorders. There was a trend, how-
ever, suggesting that the effects of therapy in PD
may be smaller than in the other anxiety disorders
(BDI: p = 0.09; HAMD-17: p = 0.07). For BDI-II there
was also a trend (p = 0.07) suggesting that the effects
in SAD were larger than those in GAD.
Because baseline severity was lower in the anxiety
disorders than in MDD, we selected the studies using
the BDI in which baseline severity was comparable to
those in the MDD studies (a mean baseline BDI score
between 19 and 29, suggesting moderate to severe de-
pression (Beck et al. 1988). There was a trend (p = 0.09)
suggesting that treatment of anxiety resulted in larger
effects in GAD than in PD. Unfortunately, no studies
in SAD were available in which the baseline BDI
score was between 19 and 29.
Comparison of treatment of anxiety disorders
with that of MDD
First, we compared the pooled effects on depression of
the three anxiety disorders and compared these with
Table 2. Relative effects of cognitive and behavioural therapies for GAD, SAD, PD and MDD on depression: Hedges’ ga
Ncmp g 95% CI MD 95% CI I
2 95% CI pb NNT
All depression measures –c 0.13/0.35
GAD 21 0.68 0.53–0.82 12 0–48 2.70
SAD 19 0.79 0.53–1.04 71 50–81
PD 28 0.47 0.21–0.73 73 59–81 3.85
MDD 42 0.81 0.67–0.94 64 47–73 2.30
Only low risk of bias –c 0.45/0.59
GAD 6 0.53 0.31–0.76 25 0–70 3.42
SAD 4 0.59 0.20–0.98 65 0–86 3.09
PD 2 0.85 0.30–1.40 45 NAd 2.21
MDD 19 0.75 0.57–0.93 65 36–77 2.48
BDI 0.12/0.09
GAD 16 0.83 0.66–1.00 6.14 4.88–7.39 0 0–45 2.26
SAD 11 0.69 0.42–0.97 5.12 3.63–6.61 48 0–73 2.67
PD 26 0.48 0.21–0.74 4.10 2.06–6.14 73 59–81 3.76
MDD 21 0.85 0.63–1.08 7.69 5.88–9.50 65 39–77 2.21
BDI, only between 19 and 29e 0.19/0.09
GAD 5 0.84 0.52–1.16 7.02 4.51–9.53 0 0–64 2.23
PD 7 0.28 −0.29 to 0.85 2.89 −3.13 to 8.90 74 27–86 6.41
MDD 20 0.84 0.60–1.07 7.52 5.66–9.38 66 40–78 2.23
BDI-II 0.001/0.07
GAD 5 0.36 0.15–0.58 3.11 1.27–4.94 0 0–64 5.00
SAD 4 1.20 0.33–2.06 9.71 4.30–15.11 87 62–93 1.66
MDD 14 0.82 0.68–0.96 9.20 7.11–11.28 0 0–47 2.28
HAMD-17 0.02/0.07
GAD 5 0.83 0.41–1.24 4.98 2.96–7.00 51 0–80 2.26
SAD 4 0.79 0.58–1.00 3.40 0.37–6.42 85 48–92
PD 4 −0.09 −0.88 to 0.70 −0.39 −5.13 to 4.35 80 13–90 [20.00]
MDD 22 0.79 0.58–1.00 4.91 3.46–6.36 74 58–82 2.36
GAD, Generalized anxiety disorder; SAD, social anxiety disorder; PD, panic disorder; MDD, major depressive disorder;
BDI, Beck Depression Inventory; HAMD-17, Hamilton Depression Rating Scale; CI, Confidence interval; MD, mean difference
(not standardized); Ncomp, number of comparisons; NNT, number needed to treat.
a According to the random effects model.
b The first p value in this column indicates whether the difference between the effect sizes among GAD, SAD, panic
disorder and MDD is significant; in the second p value MDD is not included (comparison only among anxiety disorders).
c The mean difference is only meaningful when one instrument is used (because it gives the exact points for this
instrument).
d The 95% CI of I2 cannot be calculated when the number of studies is 42.
e No study on social anxiety disorder using the BDI as outcome instrument was available.
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the effects from the depression studies. The results are
presented in Table 3. As can be seen, the difference be-
tween treatments of anxiety disorders and treatments
of depression was small, but significant (p = 0.04),
with the effects of anxiety treatments on depression
being somewhat smaller (g = 0.61, 95% CI 0.49–0.74)
than depression treatments (g = 0.81, 0.67–0.94).
Heterogeneity was moderate to high in both groups
of studies (I2 = 62 and 64, respectively). This difference
was not significant anymore, however, when we only
Fig. 2. Forest plot of effects of treatment of anxiety disorders on depression: Hedges’ g.
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looked at studies with low risk of bias (p = 0.22). When
we looked at each of the three instruments separately,
we found no significant difference between anxiety
and depression treatments, except for the HAMD-17
(p = 0.04). When we limited the anxiety treatment stud-
ies to those in which patients had moderate to severe
depression at baseline (BDI: 19–29), we also found no
significant difference between anxiety and depression
treatments.
Second, we conducted subgroup analyses in which
we entered each of the anxiety disorders separately
and compared them with MDD (results are presented
in Table 2). When all depression measures were pooled
there was no significant difference between the treat-
ments for the four disorders, and that was also true
when the analyses were limited to studies with low
risk of bias. When we limited the analyses to each of
the three specific depression measures, we found no
significant difference for BDI, but we did find these
for the BDI-II and HAMD-17. For the BDI-II the results
suggested larger effects for SAD and smaller effects for
GAD (p = 0.001). For HAMD-17 the results suggested
that the effects for SAD were smaller and those for
panic were not significantly different from zero.
However, the number of studies in each of the groups
was small and heterogeneity was considerable in sev-
eral of the subgroups. These results should, therefore,
be considered with caution.
Within-group effect sizes
The within-group effect sizes of the treatments of anx-
iety disorders and MDD are given in Table 4. As can be
seen the effect sizes did not differ between the three
anxiety disorders, but they were highly significant
when MDD was included (p < 0.001), with consider-
ably larger effect sizes for MDD than for the anxiety
disorders. The same pattern of no significant difference
among the three anxiety disorders and the significant
difference when MDD was added as a subgroup,
was also found when we limited the studies to those
with low risk of bias, and also when we looked at
the BDI, BDI-II and HAMD-17 separately, as well as
with the studies in which the patients with anxiety dis-
orders scored between 19 and 29 on the BDI.
Multivariate meta-regression analyses
We conducted multivariate regression analyses with
the effects of treatment on depression as the dependent
Table 3. Comparative effects of treatment of anxiety disorders on depression, compared with treatment of MDD: Hedges’ ga
Ncmp g 95% CI MD 95% CI I
2 95% CI pb NNT
All depression measures
All anxiety disorders 68 0.64 0.51–0.77 –c 62 49–70 0.09 2.86
MDD 42 0.81 0.67–0.94 –c 64 47–73 2.30
Only low risk of bias
All anxiety disorders 12 0.59 0.40–0.77 –c 42 0–69 0.22 3.09
MDD 19 0.75 0.57–0.93 –c 65 36–77 2.48
BDI
All anxiety disorders 53 0.64 0.49–0.80 4.95 3.69–6.22 62 47–71 0.13 2.86
MDD 21 0.85 0.63–1.08 7.69 5.88–9.50 65 39–77 2.21
BDI, only between 19 and 29
All anxiety disorders 12 0.52 0.15–0.89 4.91 1.61–8.21 66 25–80 0.15 3.50
MDD 20 0.84 0.60–1.07 7.52 5.66–9.38 66 40–78 2.23
BDI-II
All anxiety disorders 9 0.65 0.33–0.97 6.03 2.98–9.08 71 30–84 0.34 2.82
MDD 14 0.82 0.68–0.96 9.20 7.11–11.28 0 0–47 2.28
HAMD-17
All anxiety disorders 13 0.52 0.14–0.90 2.81 0.75–4.87 80 64–87 0.22 3.50
MDD 22 0.79 0.58–1.00 4.91 3.46–6.36 74 58–82 2.36
MDD, Major depressive disorder; BDI, Beck Depression Inventory; HAMD-17, Hamilton Depression Rating Scale, CI,
Confidence interval; MD, mean difference (not standardized); Ncmp, number of comparisons; NNT, number needed to treat.
a According to the random effects model.
b The p value in this column indicates whether the difference between the effect sizes across depression and anxiety
disorders is significant.
c The mean difference is only meaningful when one instrument is used (because it gives the exact points for this
instrument).
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variable. In the first model we pooled all trials on anx-
iety disorders and tested whether the effects on depres-
sion differed from the studies on MDD (dummy
variable). In these analyses we adjusted for characteris-
tics of the participants (mean baseline depression
severity, type of recruitment, target group), the treat-
ments (format, number of sessions) and the study
(risk of bias, type of control group, and country
where the study was conducted). The results of these
analyses are presented in Table 5. As can be seen
there was a non-significant trend suggesting that the
effects of treatment of MDD on depression was larger
than treatment of anxiety disorders (p < 0.1).
In the second multivariate meta-regression model we
entered dummy variables for each of the anxiety disor-
ders separately, while using MDD as the reference
group, and we adjusted for the same variables as in the
first model. As can be seen in Table 5, we found that the
effects of treatment of PDondepressionwas significantly
smaller than the effects of treatment of depression. The
effects of treatment of GAD and SAD was not signifi-
cantly smaller than treatment of depression.
In the third model, we did not include MDD and
entered a dummy variable for each of the anxiety dis-
orders (with GAD as reference). As can be seen, we
found no significant difference for the three anxiety
Table 4. Within group effect sizes of treatment of anxiety disorders on depression, compared with treatment of MDD: Hedges’ ga
Ncmp g 95% CI MD 95% CI I
2 95% CI pb NNT
All depression measures –c <0.001/0.20
GAD 21 0.87 0.76–0.98 55 16–71 2.16
SAD 19 0.73 0.57–0.89 78 65–85 2.54
PD 28 0.91 0.78–1.05 62 40–74 2.08
MDD 42 1.50 1.31–1.69 90 88–92 1.40
Only low risk of bias <0.001/0.12
GAD 6 0.93 0.76–1.10 56 0–80 2.04
SAD 4 0.65 0.38–0.93 77 0–90 2.82
PD 2 1.30 0.61–2.00 81 –d 1.56
MDD 19 1.52 1.21–1.83 94 93–95 1.39
BDI <0.001/0.09
GAD 16 0.81 0.65–0.98 7.01 5.42–8.60 66 35–79 2.30
SAD 11 0.70 0.53–0.87 5.99 4.38–7.54 53 0–75 2.63
PD 26 0.94 0.80–1.08 7.76 6.82–8.70 63 39–75 2.02
MDD 21 1.47 1.25–1.69 12.61 11.43–13.80 79 68–85 1.42
BDI, only between 19–29e <0.001/0.30
GAD 5 0.97 0.65–1.30 8.74 6.16–11.33 69 0–86 1.97
PD 7 0.78 0.62–0.94 9.28 7.60–10.95 0 0–58 2.39
MDD 20 1.49 1.26–1.72 12.45 11.27–13.62 80 70–86 1.41
BDI-II 0.01/0.53
GAD 5 0.94 0.75–1.13 9.00 6.29–11.71 64 0–84 2.02
SAD 4 0.79 0.37–1.21 8.55 3.89–13.22 83 40–92 2.36
MDD 14 1.31 1.14–1.47 13.81 10.64–16.98 59 11–76 1.55
HAMD-17 <0.001/0.68
GAD 5 0.82 0.43–1.22 5.22 2.81–7.63 80 38–90 2.28
SAD 4 0.74 0.26–1.22 3.60 1.48–5.71 91 79–95 2.50
PD 4 0.61 0.32–0.90 4.26 2.01–6.51 51 0–82 2.99
MDD 22 1.72 1.39–2.04 9.92 7.62–12.22 94 92–95 1.29
GAD, Generalized anxiety disorder; SAD, social anxiety disorder; PD, panic disorder; MDD, major depressive disorder;
BDI, Beck Depression Inventory; HAMD-17, Hamilton Depression Rating Scale; CI, Confidence interval; MD, mean difference
(not standardized); Ncmp, number of comparisons; NNT, Numbe needed to treat.
a According to the random effects model.
b The first p value in this column indicates whether the difference between the effect sizes among GAD, SAD, panic
disorder and MDD is significant; in the second p value MDD is not included (comparison only among anxiety disorders).
c The mean difference is only meaningful when one instrument is used (because it gives the exact points for this
instruments).
d The 95% CI of I2 cannot be calculated with less than three studies.
e No study on social anxiety disorder using the BDI as outcome instrument was available.
Effects of cognitive and behavioural therapies for anxiety disorders on depression 3459
http://dx.doi.org/10.1017/S0033291716002348
Downloaded from http:/www.cambridge.org/core. Vrije Universiteit Amsterdam, on 25 Nov 2016 at 12:19:18, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
disorders on depression (p > 0.1), but that may be
related to the small number of studies.
Discussion
In this meta-analysis we examined the effects of cogni-
tive behavioural treatments of three major anxiety dis-
orders, GAD, SAD and PD, on depression. We found
that baseline severity of depression differed across
the three anxiety disorders, with the highest levels of
baseline depression for GAD, and the lowest for
SAD, but this did not reach levels of significance for
all depression measures. When compared with depres-
sion trials, baseline depression severity was signifi-
cantly lower in all three anxiety disorders. However,
the average BDI score in the trials on anxiety disorders
indicated that participants were mildly to moderately
depressed, and there was a considerable number of
studies in which patients had moderate to severe de-
pression. These findings once more illustrate that co-
morbid depression is an important problem in anxiety
disorders, which is in line with the well-established
high levels of co-morbidity of anxiety disorders and
depression.
We also found that the effects of treatments of anx-
iety disorders on depression were overall moderate
to large, and limiting the analyses to studies with
low risk of bias did not affect these overall outcomes
very much. It could be possible that this is an indirect
effect, in which a reduction of anxiety results in lower
Table 5. Standardized regression coefficients of characteristics of studies on cognitive and behavioural treatments of anxiety disorders on
depression and of depression: Multivariate metaregression analyses
Model 1: All anxiety
disorders v. MDD
Model 2: Separate anxiety
disorders and MDD
Model 3: Separate anxiety
disorders, no MDD
Coeff. 95% CI p Coeff. 95% CI p Coeff. 95% CI p
Anxiety v. depressive
disorder
2.61 −1.43 to 6.64 0.20
Disorder MDD Ref.
GAD −1.64 −6.04 to 2.75 0.46 Ref.
SAD −1.51 −6.70 to 3.68 0.56 1.25 −3.96 to 6.45 0.63
PD −3.83 −8.30 to 0.65 0.09 −1.59 −5.85 to 2.67 0.46
Risk of bias (continuous) −0.50 −1.50 to 0.51 0.33 −0.76 −1.81 to 0.30 0.16 −1.25 −2.72 to 0.23 0.10
Baseline depression severity 0.21 −0.06 to 0.49 0.13 0.23 −0.06 to 0.51 0.12 0.19 −0.20 to 0.57 0.33
Recruitment Community Ref. Ref.
Clinical −1.33 −4.22 to 1.57 0.36 −1.32 −4.84 to 2.20 0.46 0.27 −4.13 to 4.66 0.90
Other 2.00 −2.42 to 6.42 0.37 2.21 −2.18 to 6.60 0.32 2.84 −3.64 to 9.32 0.38
Target group Adults Ref. Ref.
Older
adults
−1.69 −7.47 to 4.09 0.56 −2.91 −9.81 to 3.99 0.40 −2.72 −10.62 to 5.18 0.49
Other −4.56 −9.75 to 0.62 0.08 −4.70 −9.86 to 0.47 0.07 −10.92 −19.66 to 2.18 0.02
Format Individual Ref. Ref.
Group −1.20 −4.05 to 1.65 0.40 −1.60 −4.50 to 1.29 0.27 −2.53 −6.08 to 1.03 0.16
Guided
self-help
−1.98 −5.76 to 1.81 0.30 −1.87 −5.70 to 1.96 0.33 −0.69 −5.73 to 4.34 0.78
Other −0.27 −5.27 to 4.73 0.91 −0.64 −5.61 to 4.34 0.80 2.05 −7.52 to 11.61 0.67
N sessions (continuous) −0.13 −0.42 to 0.16 0.39 −0.15 −0.45 to 0.14 0.30 −0.15 −0.51 to 0.21 0.40
Control group Waiting list Ref. Ref.
Care as
usual
−1.63 −5.43 to 2.16 0.39 −1.17 −4.97 to 2.63 0.54 0.07 −6.93 to 7.07 0.98
Placebo −2.54 −8.37to 3.30 0.39 −2.09 −7.90 to 3.71 0.47 −1.88 −9.15 to 5.39 0.61
Other −1.49 −6.07 to 3.10 0.52 −0.89 −5.56 to 3.78 0.71 −1.83 −11.75 to 8.09 0.71
Country Europe Ref. Ref.
North
America
−0.67 −2.97 to 1.62 0.56 −0.51 −2.84 to 1.83 0.67 −0.69 −3.58 to 2.19 0.63
Other −1.73 −5.45 to 1.99 0.36 −1.32 −5.09 to 2.46 0.49 −1.44 −7.15 to 4.26 0.61
Intercept 5.85 −1.17 to 12.87 0.10 8.95 −1.53 to 19.43 0.09 8.17 −2.55 to 18.89 0.13
MDD, Major depressive disorder; GAD, Generalized anxiety disorder; SAD, social anxiety disorder; PD, panic disorder;
Coeff., regression coefficient; CI, confidence interval.
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levels of depression. It is also possible, however, that
there is a direct effect of the treatments on depression,
and that the same techniques that improve anxiety
symptoms also improve depression. These findings
are in line with earlier meta-analyses of each of the
anxiety disorders, showing that these treatments also
have considerable effects on depression (Mitte, 2005;
Hunot et al. 2007; Acarturk et al. 2009; Sánchez-Meca
et al. 2010; Cuijpers et al. 2014).
We found few indications that the effects of the treat-
ments on depression differed consistently across the
three anxiety disorders. The findings differed for each
of the depression measures that were used, but these
findings were obscured by high levels of heterogeneity
and small numbers of studies in some categories. The
overall analyses, bivariate and multivariate, suggested
that no major differences existed between the effects on
depression of the treatments for the three anxiety disor-
ders. These findings should be considered with caution,
because not finding a significant difference is no evi-
dence for the absence of a difference, and the results
could be related to the small number of trials in some
comparisons and heterogeneity in the analyses.
However, the notion that there are no or only rela-
tively small differences is interesting. It suggests that
the effects of treatment of anxiety disorders on depres-
sion occur across disorders and can be seen as support
for a transdiagnostic treatment approach in which
the same treatment is given to patients with different
disorders (Craske, 2012). If treatment of an anxiety dis-
order also improves depression, maybe a specific focus
on this disorder may not be needed and the specific
diagnosis may not be so relevant for the content of
the treatment. A growing number of randomized trials
find that transdiagnostic therapies are indeed effective
in the treatment of depression and anxiety disorders
(Newby et al. 2015). Our findings however cannot be
seen as sufficient evidence for supporting transdiag-
nostic treatments, as these findings could also be
seen as indirect effects and it would be needed to
show that CBT interventions for anxiety reduce de-
pression in a sample of only depressed individuals
(and that CBT interventions for MDD work with PD,
SAD, and GAD). Moreover, one could also argue
that specific treatments aimed at specific disorders in
specific ways may not be mandatory for the treatments
to be effective, if any of these treatments results in
effects similar to what we found in this meta-analysis.
We also could challenge the idea of diagnoses in gen-
eral because they are not only highly co-morbid, but
also respond to the same treatments.
We also compared treatments for MDD with treat-
ments for anxiety disorders, and found some indica-
tions that treatment of MDD has somewhat larger
effects than treatments of anxiety disorders, especially
in the within-group effect sizes. However, the con-
trolled effect sizes were relatively small and were no
longer significant after adjusted for other characteris-
tics. We found some indications that the effects of treat-
ment of PD on depression are somewhat smaller than
those of treatments of GAD, SAD and MDD. Overall
these results can also be seen as support of transdiag-
nostic treatments.
There are several limitations of this meta-analysis.
First, the number of trials was relatively small for sev-
eral subgroup analyses, especially when considering
the three depression outcome measures separately.
Finding no difference while the number of studies is
small cannot be considered as evidence that there
is no difference. Furthermore, risk of bias was consid-
erable in most of the included studies. Although we
found no association between risk of bias and out-
come, the results should be considered with caution
because of this. Another limitation is that most of our
results are based on subgroup and meta-regression
analyses. The outcomes of these analyses are indirect
and can only point at possible differences between
studies, and new randomized trials are needed to
confirm such findings. We also examined only short-
term effects of treatments, because most studies did
not report longer-term outcomes and the studies that
did report them used many different follow-up peri-
ods, making comparisons impossible. We should also
acknowledge that the treatments differed considerably
across disorders. Although we limited this meta-
analysis to studies on cognitive behaviour therapies,
this is still a very broad category with many different
types of treatment. Because of these limitations, the
results of this meta-analysis should be considered with
caution.
Despite these limitations we can conclude that
patients participating in trials of treatments of anxiety
disorders have high levels of depression, that these
treatments have moderate to large effects on depres-
sion, that these effects are probably comparable across
GAD, SAD and PD, and that they are comparable to
those of direct treatments of depression.
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